Sign In
MCK.US
id: 539

McKesson Corporation (MCK) $141 MM Investors Settlement

N.D. California
Court
18-CV-06525
Case number
10/24/2013
Class period Start
01/25/2017
Class period End
05/10/2023
Claim deadline
McKesson Corporation (MCK) agreed to pay up to $141 million to settle a securities class action lawsuit to avoid further litigation.

The complaint alleged that the Company and its Leaders made false and/or misleading statements and/or failed to disclose that:
  • McKesson and several of its industry peers colluded to fix the price of certain generic drugs;
  • the collusive conduct constituted a violation of federal antitrust laws;
  • consequently, McKesson’s revenues were, in part, the result of illegal conduct and were therefore unsustainable;
  • McKesson lacked effective internal controls over financial reporting.
Case Status
Disbursement
Alleged Offence
Other
Suspected Party
Other
Security Type
Stocks
Trade Direction
Long
Filing date
10/25/2018
Plaintiffs
Trust Fund for Operating Engineers
Attorneys
Robbins Geller Rudman & Dowd LLP (San Diego, CA)
Defendants
John H. Hammergren, James Beer
Judge
Hon. Charles R. Breyer
Administrator
Gilardi & Co LLC
Court hearing date
06/02/2023
Exclusion deadline
05/12/2023
Objection deadline
05/12/2023
Trades matching type
FIFO
Disbursement date
11/20/2024
+$141,000,000
Cash Settlement Amount

McKesson Corporation

McKesson Corporation provides healthcare services in the United States and internationally. It operates through four segments: U.S. Pharmaceutical, Prescription Technology Solutions (RxTS), Medical...

    Ticker
    MCK.US
    ISIN
    US58155Q1031
    CIK
    927653
    Sector
    Healthcare
    Industry
    Medical Distribution
    Country
    USA
    Address
    6555 State Highway 161, Irving, TX, United States, 75039